News

Countries with high malaria burden don’t receive research funding


 

Photo by Rhoda Baer

Researchers in the lab

A new study has revealed inequalities in malaria research funding in sub-Saharan Africa.

The study showed that some countries with a high malaria burden—such as Sierra Leone, Congo, Central African Republic, and Guinea—received little to no funding for malaria research in recent years.

However, other countries—such as Tanzania, Uganda, and Kenya—received close to $100 million in funding for malaria research.

Michael Head, PhD, of the University of Southampton in the UK, and his colleagues reported these findings in The Lancet Global Health.

“We have been able to provide a comprehensive overview of the landscape of funding for malaria in sub-Saharan Africa, a massive area where around 90% of worldwide malaria cases occur,” Dr Head said.

“We’ve shown that there are countries that are being neglected, and the global health community should reconsider strategies around resource allocation to reduce inequities and improve equality.”

For this study, Dr Head and his colleagues analyzed funding data spanning the period from 1997 to 2013. The data were sourced from 13 major public and philanthropic global health funders, as well as from funding databases.

The researchers ranked 45 countries according to the level of malaria research funding they received.

All of the countries studied received funding for malaria control, which includes investment for bed nets, public health schemes, and antimalarial drugs.

However, 8 of the 45 countries did not receive any funding related to malaria research. This included Central African Republic, Sierra Leone, and Congo—countries with a “reasonably high” malaria burden/mortality rate, according to Dr Head and his colleagues.

In all, there were 333 research awards, totaling $814.4 million. The countries that received the most research funding were Tanzania ($107.8 million), Uganda ($97.9 million), and Kenya ($92.9 million).

The 8 countries that received no research funding were Cape Verde, Botswana, Djibouti, Central African Republic, Mauritania, Congo, Chad, and Sierra Leone.

Dr Head and his colleagues suggested that the reason for the disparity in funding allocation could be, in part, due to the presence of established high-quality research infrastructure in countries such as Tanzania and Kenya, and political instability and poor healthcare infrastructures in lower-ranked nations such as Central African Republic or Sierra Leone.

“[N]ew investment in malaria research and development in these areas can encourage the development of improved health systems,” Dr Head said. “Many countries in sub-Saharan Africa simply do not have an established research infrastructure, and it is difficult for research funders to make investments in these settings.”

“Ultimately, however, there are neglected populations in these countries who suffer greatly from malaria and other diseases. Investments in health improve the wealth of a nation, and we need to be smarter with allocating limited resources to best help to reduce clear health inequalities.”

Recommended Reading

FDA unveils plan to eliminate orphan designation backlog
MDedge Hematology and Oncology
Single-dose NEPA found non-inferior to aprepitant/granisetron
MDedge Hematology and Oncology
Developments on the malaria front
MDedge Hematology and Oncology
Kids’ self-reports of symptoms, side effects reliable
MDedge Hematology and Oncology
Tafenoquine reduces relapse risk in patients with P vivax malaria
MDedge Hematology and Oncology
Malaria infection can lead to chronic bone loss
MDedge Hematology and Oncology
Malaria drug could help identify bloodstains
MDedge Hematology and Oncology
Group uses mobile lab to track spread of Zika in Brazil
MDedge Hematology and Oncology
Indian govt. waited months to report Zika cases
MDedge Hematology and Oncology
Zika virus spread undetected in the Americas, team says
MDedge Hematology and Oncology